Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ORKA NASDAQ:PHAT NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$20.69-3.3%$21.80$19.69▼$28.35$3.66B0.861.62 million shs1.62 million shsORKAOruka Therapeutics$58.34-5.8%$55.67$9.54▼$91.00$3.74B-0.22.36 million shs1.91 million shsPHATPhathom Pharmaceuticals$11.39-4.0%$11.64$3.69▼$18.31$946.70M0.571.50 million shs1.31 million shsTLXTelix Pharmaceuticals$10.28-2.7%$9.67$6.28▼$18.49$3.58B0.08131,676 shs86,682 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-3.32%-5.09%-6.68%-9.85%-7.05%ORKAOruka Therapeutics-5.80%-11.18%-15.35%+78.52%+479.92%PHATPhathom Pharmaceuticals-4.04%-6.79%-13.65%-10.74%+178.48%TLXTelix Pharmaceuticals-2.65%-5.08%-4.28%+60.12%-38.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$20.69-3.3%$21.80$19.69▼$28.35$3.66B0.861.62 million shs1.62 million shsORKAOruka Therapeutics$58.34-5.8%$55.67$9.54▼$91.00$3.74B-0.22.36 million shs1.91 million shsPHATPhathom Pharmaceuticals$11.39-4.0%$11.64$3.69▼$18.31$946.70M0.571.50 million shs1.31 million shsTLXTelix Pharmaceuticals$10.28-2.7%$9.67$6.28▼$18.49$3.58B0.08131,676 shs86,682 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-3.32%-5.09%-6.68%-9.85%-7.05%ORKAOruka Therapeutics-5.80%-11.18%-15.35%+78.52%+479.92%PHATPhathom Pharmaceuticals-4.04%-6.79%-13.65%-10.74%+178.48%TLXTelix Pharmaceuticals-2.65%-5.08%-4.28%+60.12%-38.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.72Moderate Buy$31.1850.68% UpsideORKAOruka Therapeutics 2.82Moderate Buy$120.80107.06% UpsidePHATPhathom Pharmaceuticals 2.88Moderate Buy$25.00119.49% UpsideTLXTelix Pharmaceuticals 2.78Moderate Buy$21.13105.50% UpsideCurrent Analyst Ratings BreakdownLatest PHAT, ORKA, ACAD, and TLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$120.005/14/2026ORKAOruka Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$151.005/8/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $32.005/1/2026ACADACADIA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)4/30/2026ORKAOruka Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$120.004/29/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $120.004/28/2026ORKAOruka Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $100.004/27/2026ORKAOruka Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.004/27/2026ORKAOruka Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$78.00 ➝ $160.004/27/2026ORKAOruka Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$200.004/27/2026ORKAOruka Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $151.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.31$0.86 per share24.12$7.25 per share2.85ORKAOruka TherapeuticsN/AN/AN/AN/A$9.69 per shareN/APHATPhathom Pharmaceuticals$175.11M5.19N/AN/A($6.14) per share-1.86TLXTelix Pharmaceuticals$803.79M4.34$0.04 per share250.45$1.23 per share8.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.209.4025.8625.9134.30%9.61%7.07%8/5/2026 (Estimated)ORKAOruka Therapeutics-$105.43M-$1.94N/AN/AN/AN/A-26.16%-25.00%N/APHATPhathom Pharmaceuticals-$221.25M-$2.12N/A7.30N/A-76.77%N/A-44.29%8/6/2026 (Estimated)TLXTelix Pharmaceuticals-$7.12MN/AN/A60.47N/AN/AN/AN/AN/ALatest PHAT, ORKA, ACAD, and TLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ORKAOruka Therapeutics-$0.52-$0.48+$0.04-$0.48N/AN/A5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million3/12/2026Q4 2025ORKAOruka Therapeutics-$0.61-$0.45+$0.16-$0.45N/AN/A2/26/2026Q4 2025ACADACADIA Pharmaceuticals$0.12$1.60+$1.48$1.60$292.54 million$298.00 million2/26/2026Q4 2025PHATPhathom Pharmaceuticals-$0.09-$0.08+$0.01-$0.29$57.44 million$57.58 million2/20/2026H2 2025TLXTelix Pharmaceuticals$0.0493-$0.01-$0.0593-$0.0070$421.50 million$206.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48ORKAOruka TherapeuticsN/A23.7623.76PHATPhathom PharmaceuticalsN/A2.212.16TLXTelix Pharmaceuticals1.081.431.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ORKAOruka Therapeutics56.44%PHATPhathom Pharmaceuticals99.01%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%ORKAOruka Therapeutics23.49%PHATPhathom Pharmaceuticals9.33%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableORKAOruka TherapeuticsN/A60.31 million46.15 millionN/APHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableTLXTelix Pharmaceuticals1,184339.38 millionN/AN/APHAT, ORKA, ACAD, and TLX HeadlinesRecent News About These CompaniesTelix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving UpMay 18 at 7:00 PM | seekingalpha.comIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms DosingMay 18 at 5:00 PM | globenewswire.comTelix Pharmaceuticals Ltd ADR TLXMay 17 at 8:34 AM | morningstar.comMTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesMay 15, 2026 | globenewswire.comTelix Issues New Shares to Complete Deferred ImaginAb Acquisition PaymentMay 10, 2026 | theglobeandmail.comMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic SurgeryMay 8, 2026 | businesswire.comChristian Behrenbruch Buys 34,500 Shares of Telix Pharmaceuticals (NASDAQ:TLX) StockMay 8, 2026 | americanbankingnews.comChristian Behrenbruch Buys 33,435 Shares of Telix Pharmaceuticals (NASDAQ:TLX) StockMay 8, 2026 | americanbankingnews.comChristian Behrenbruch Acquires 33,435 Shares of Telix Pharmaceuticals (NASDAQ:TLX) StockMay 7, 2026 | insidertrades.comInsider Buying: Telix Pharmaceuticals (NASDAQ:TLX) CEO Buys 33,435 Shares of StockMay 6, 2026 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) CEO Christian Behrenbruch Acquires 34,500 SharesMay 6, 2026 | marketbeat.comNew Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCCMay 4, 2026 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 - SlideshowMay 2, 2026 | seekingalpha.comInsider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of SharesMay 1, 2026 | finance.yahoo.comTelix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of "Moderate Buy" from AnalystsMay 1, 2026 | marketbeat.comTLX101-Px (Pixlumi®) MAA Accepted in EuropeApril 30, 2026 | globenewswire.comHow TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) InvestorsApril 30, 2026 | finance.yahoo.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 TranscriptApril 30, 2026 | seekingalpha.comTelix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears EndApril 29, 2026 | marketbeat.comOPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate CancerApril 29, 2026 | globenewswire.comEducational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio ApproachApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 20263 Small-Cap Stocks to Buy as the Russell 2000 Extends Its RallyBy Chris Markoch | May 11, 2026PHAT, ORKA, ACAD, and TLX Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$20.69 -0.71 (-3.32%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$20.68 -0.01 (-0.05%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Oruka Therapeutics NASDAQ:ORKA$58.34 -3.59 (-5.80%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$60.60 +2.26 (+3.87%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Phathom Pharmaceuticals NASDAQ:PHAT$11.39 -0.48 (-4.04%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$11.40 +0.00 (+0.04%) As of 07:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Telix Pharmaceuticals NASDAQ:TLX$10.28 -0.28 (-2.65%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$10.60 +0.33 (+3.16%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade? Why Trump’s Amazon Stock Sale May Not Matter at All Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
